David Parker, Mike Evans
David Parker, a general partner in Ampersand Capital Partners, and Mike Evans, operating partner at Ampersand, have joined the board of Dutch firm Genome Diagnostics, which said this week that Ampersand invested an undisclosed amount in the firm. Ampersand, as a result, became minority shareholders in GenDx.